Treatment of early diffuse systemic sclerosis skin disease.

Tracy M Frech, Victoria K Shanmugam, Ami A Shah, Shervin Assassi, Jessica K Gordon, Faye N Hant, Monique E Hinchcliff, Virginia Steen, Dinesh Khanna, Cristiane Kayser, Robyn T Domsic

Clinical and experimental rheumatology 2013 Mar-Apr

filter terms:

Diffuse systemic sclerosis carries a high morbidity and mortality. The Prospective Registry of Early Systemic Sclerosis (PRESS), a multicentre incident cohort study of patients with early diffuse cutaneous systemic sclerosis, has the goal of advancing the understanding of disease pathogenesis and identifying novel biomarkers. In this review, PRESS investigators discuss the evidence pertaining to the more commonly used treatments for early diffuse SSc skin disease including methotrexate, mycophenolate, cyclophosphamide, azathioprine, and intravenous immunoglobulin. This review highlights the unmet need for effective treatment in early diffuse SSc as well as its more rigorous study. Nonetheless, the PRESS investigators aim to decrease intra- and inter-institutional variability in prescribing in order to improve the understanding of the clinical course of early diffuse SSc skin disease.

Citation

Tracy M Frech, Victoria K Shanmugam, Ami A Shah, Shervin Assassi, Jessica K Gordon, Faye N Hant, Monique E Hinchcliff, Virginia Steen, Dinesh Khanna, Cristiane Kayser, Robyn T Domsic. Treatment of early diffuse systemic sclerosis skin disease. Clinical and experimental rheumatology. 2013 Mar-Apr;31(2 Suppl 76):166-71